Harnessing AI for the Early Detection of Pancreatic Cancer

More than 50% of pancreatic cancers are diagnosed at stage 4, which is why survival rates for this disease are so low. There is very little known about the causes of pancreatic cancer and there are currently no effective screening tests for the disease. 

By increasing the number of patients who are diagnosed in the earlier, more treatable stages of this disease, we can ultimately see survival rates improve. Early detection has been noted as an unmet need for the clinical and research communities and is one of our biggest funding priorities.

Recent genetic analyses on pancreatic cancer indicated that the genetic timeline for progression of this disease from initiation to terminal metastases is nearly two decades, suggesting a wide window of opportunity for early detection.

For many years, research into early detection has primarily focused on circulating biomarkers of early pancreatic cancer in the blood.  To make a real, measurable impact, it is necessary to localize early disease with imaging, which can be incredibly challenging.

What the researchers hope to gain from this study:

• Real-world imaging data and blood biomarkers to better understand how quantitative tools (radiomics/AI) can be used to detect pancreatic cancer at an earlier, curable stage.
• Identification of new biomarker targets and insights into biology and use of radiomics/AI.
• New intellectual property and alliances with industry and foundations to accelerate the translation of their discoveries to patient care.
• The opportunity to test advanced imaging methods in patients at high risk of pancreatic cancer.